<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01019317</url>
  </required_header>
  <id_info>
    <org_study_id>2009-0781</org_study_id>
    <nct_id>NCT01019317</nct_id>
  </id_info>
  <brief_title>Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)</brief_title>
  <official_title>A Phase II Study of Twice Daily Cytarabine and Fludarabine in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if the combination of fludarabine and
      cytarabine can help to control Acute Myelogenous Leukemia (AML), High-Risk Myelodysplastic
      Syndrome (MDS) or Chronic Myeloid Leukemia (CML) in myeloid blast crisis. The safety of this
      drug combination will also be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drugs Fludarabine is designed to make cancer cells less able to repair damaged DNA
      (the genetic material of cells). This may increase the likelihood of the cells dying.

      Cytarabine is designed to insert itself into DNA and stop the DNA from repairing itself.

      Study Drug Administration:

      If you are found to be eligible to take part in this study, you will receive fludarabine and
      cytarabine.

      During each cycle (about 4-6 weeks), you will receive the study drugs for up to 5 days and
      you will be watched by the study staff for about 1 month.

      Induction (Cycle 1):

      For 3, 4, or 5 days during Days 1-5 of Cycle 1, you will receive fludarabine by vein over
      15-30 minutes 2 times a day (about every 12 hours).

      For 3, 4, or 5 days during Days 1-5 of Cycle 1, you will receive cytarabine by vein over
      about 2 hours 2 times a day (about every 12 hours).

      If the cancer does not completely respond after Cycle 1, you may repeat induction (Cycle 1).

      If the cancer completely responds, you will begin the consolidation cycles.

      Consolidation (Cycles 2-7):

      For 3 or 4 days during Days 1-4 of Cycles 2-7, you will receive fludarabine by vein over
      15-30 minutes 2 times a day (about every 12 hours).

      For 3 or 4 days during Days 1-4 of Cycles 2-7, you will receive cytarabine by vein over about
      2 hours 2 times a day (about every 12 hours).

      Study Visits:

      At each study visit, you will be asked about any side effects you may be having and about any
      other drugs you may be taking.

      During Induction Therapy (Cycle 1):

        -  Blood (about 2 tablespoons) will be drawn for routine tests every 3-7 days.

        -  About Day 28, you may have a bone marrow aspirate to check the status of the disease.

      During Consolidation Therapy (Cycles 2-7):

        -  Blood (about 2 tablespoons) will be drawn for routine tests every 1-2 weeks.

        -  You will have a bone marrow aspirate every 2-3 cycles to check the status of the
           disease.

      Length of Study:

      You will be able to receive the study drugs for up to about 8 months. You will be taken off
      study treatment if you have intolerable side effects, if the disease gets worse, or if the
      study doctor thinks it is in your best interest.

      Long-Term Follow-Up:

      Every 3 months for 2 years after you are off study treatment, you will be called and asked
      how you are feeling, about any side effects you may be having, and about another other drugs
      you may be taking.

      Supportive Care:

      Please talk with your doctor about drugs that you can or cannot take while you are on study.

      This is an investigational study. Cytarabine is FDA approved and commercially available as a
      frontline (first) treatment for AML. Fludarabine is FDA approved and commercially available
      for the treatment of CLL.

      The combination of these 2 drugs to treat AML, MDS, or CML in myeloid blast crisis is
      investigational.

      Up to 150 patients will take part in this study. All will be enrolled at M. D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants With a Complete Response</measure>
    <time_frame>Minimally 6 weeks (Cycle 1) up to 1 year (7 cycles)</time_frame>
    <description>Complete Response (CR) was defined as: Neutrophil count ≥ 1.0 ×109/L, Platelet count ≥ 100 ×109/L, Bone marrow aspirate ≤5% blasts and No extramedullary leukemia. Response evaluation following Induction Therapy (Cycle 1) and every 2-3 cycles during Consolidation Therapy (Cycles 2 - 7) where Cycle is 4-6 weeks.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">151</enrollment>
  <condition>Leukemia</condition>
  <condition>AML</condition>
  <condition>MDS</condition>
  <condition>CML</condition>
  <arm_group>
    <arm_group_label>Cytarabine + Fludarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fludarabine 15 mg/m^2 intravenous (IV) every 12 hours for 5 days; Cytarabine 0.5 grams/m^2 IV over 2 hours every 12 hours for 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>0.5 grams/m^2 over 2 hours(+/- 15 minutes) IV every 12 (+/-2) hours for 5 days (4 days in patients &gt; 65 years and 3 days in patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) &gt; 3).</description>
    <arm_group_label>Cytarabine + Fludarabine</arm_group_label>
    <other_name>Ara-C</other_name>
    <other_name>Cytosar</other_name>
    <other_name>DepCyt</other_name>
    <other_name>Cytosine arabinosine hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>15 mg/m^2 to be given IV over 15-30 minutes every 12 (+/- 2) hours for 5 days. (4 days in patients &gt; 65 years and 3 days in patients with PS &gt; 3).</description>
    <arm_group_label>Cytarabine + Fludarabine</arm_group_label>
    <other_name>Fludara</other_name>
    <other_name>Fludarabine Phosphate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Sign an Internal Review Board (IRB)-approved informed consent document.

          2. Age &gt;/= 12 years.

          3. Diagnosis of AML [other than acute promyelocytic leukemia (APL)] with
             refractory/relapsed disease. Patients with newly diagnosed AML will be eligible if not
             a candidate for intensive chemotherapy. Patients with high-risk (intermediate-2 or
             high by IPSS or &gt;/=10% blasts) MDS will also be eligible. Patients with chronic
             myeloid leukemia (CML) in blast crisis will be eligible as well.

          4. Eastern Cooperative Oncology Group (ECOG) performance status of &lt;/= 3 at study entry.

          5. Organ function as defined below (unless due to leukemia):

             i. Serum creatinine &lt;/= 3 mg/dL; ii. Total bilirubin &lt;/= 3 mg/dL; iii. Alanine
             aminotransferase (ALT)(Serum Glutamic Pyruvate Transaminase (SGPT)) &lt;/= 5 times upper
             limit of normal (ULN) or &lt;/= 10 times ULN if related to disease.

          6. Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy
             test within 7 days . Men must agree not to father a child and agree to use a condom if
             his partner is of child bearing potential.

        Exclusion Criteria:

          1. Pregnant or breastfeeding females.

          2. Diagnosis of acute promyelocytic leukemia (M3).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elias Jabbour, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2009</study_first_submitted>
  <study_first_submitted_qc>November 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2009</study_first_posted>
  <results_first_submitted>October 4, 2013</results_first_submitted>
  <results_first_submitted_qc>October 4, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 3, 2013</results_first_posted>
  <last_update_submitted>February 17, 2016</last_update_submitted>
  <last_update_submitted_qc>February 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myelogenous Leukemia</keyword>
  <keyword>High-Risk Myelodysplastic Syndrome</keyword>
  <keyword>Chronic myeloid leukemia</keyword>
  <keyword>CML</keyword>
  <keyword>Blast crisis</keyword>
  <keyword>Cytarabine</keyword>
  <keyword>Ara-C</keyword>
  <keyword>Cytosar</keyword>
  <keyword>DepoCyt</keyword>
  <keyword>Cytosine arabinosine hydrochloride</keyword>
  <keyword>Arabinosine Hydrochloride</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Fludarabine Phosphate</keyword>
  <keyword>Fludara</keyword>
  <keyword>Gemtuzumab Ozogamicin</keyword>
  <keyword>Mylotarg</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: 11/23/2009 through 10/25/2010. All participants recruited at UT MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Of the 151 participants enrolled, four (4) participants were excluded from the trial before treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cytarabine + Fludarabine</title>
          <description>Fludarabine 15 mg/m^2 intravenous (IV) every 12 hours for 5 days; Cytarabine 0.5 grams/m^2 IV over 2 hours every 12 hours for 5 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not Eligible</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cytarabine + Fludarabine</title>
          <description>Fludarabine 15 mg/m^2 intravenous (IV) every 12 hours for 5 days; Cytarabine 0.5 grams/m^2 IV over 2 hours every 12 hours for 5 days.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="151"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" lower_limit="20" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants With a Complete Response</title>
        <description>Complete Response (CR) was defined as: Neutrophil count ≥ 1.0 ×109/L, Platelet count ≥ 100 ×109/L, Bone marrow aspirate ≤5% blasts and No extramedullary leukemia. Response evaluation following Induction Therapy (Cycle 1) and every 2-3 cycles during Consolidation Therapy (Cycles 2 - 7) where Cycle is 4-6 weeks.</description>
        <time_frame>Minimally 6 weeks (Cycle 1) up to 1 year (7 cycles)</time_frame>
        <population>Of participants enrolled, 147 participants received treatment and were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Cytarabine + Fludarabine</title>
            <description>Fludarabine 15 mg/m^2 intravenous (IV) every 12 hours for 5 days; Cytarabine 0.5 grams/m^2 IV over 2 hours every 12 hours for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With a Complete Response</title>
          <description>Complete Response (CR) was defined as: Neutrophil count ≥ 1.0 ×109/L, Platelet count ≥ 100 ×109/L, Bone marrow aspirate ≤5% blasts and No extramedullary leukemia. Response evaluation following Induction Therapy (Cycle 1) and every 2-3 cycles during Consolidation Therapy (Cycles 2 - 7) where Cycle is 4-6 weeks.</description>
          <population>Of participants enrolled, 147 participants received treatment and were evaluable.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Two years, ten months.</time_frame>
      <desc>Of the 151 participants registered, four did not recieve treatment and were excluded from adverse event reporting.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cytarabine + Fludarabine</title>
          <description>Fludarabine 15 mg/m^2 intravenous (IV) every 12 hours for 5 days; Cytarabine 0.5 grams/m^2 IV over 2 hours every 12 hours for 5 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Liver Function</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="78" subjects_affected="78" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elias Joseph Jabbour MD/Assistant Professor</name_or_title>
      <organization>University of Texas (UT) MD Anderson Cancer Center</organization>
      <phone>713-792-4764</phone>
      <email>eharriso@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

